RU2015105588A - Антитело, специфическое к cd22, и способы его применения - Google Patents
Антитело, специфическое к cd22, и способы его применения Download PDFInfo
- Publication number
- RU2015105588A RU2015105588A RU2015105588A RU2015105588A RU2015105588A RU 2015105588 A RU2015105588 A RU 2015105588A RU 2015105588 A RU2015105588 A RU 2015105588A RU 2015105588 A RU2015105588 A RU 2015105588A RU 2015105588 A RU2015105588 A RU 2015105588A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- paragraphs
- antibody according
- amino acid
- acid sequence
- Prior art date
Links
- 102100038080 B-cell receptor CD22 Human genes 0.000 title claims abstract 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 title claims abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 14
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims abstract 10
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims abstract 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims abstract 5
- 229920001184 polypeptide Polymers 0.000 claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 4
- XMTCKNXTTXDPJX-UHFFFAOYSA-N 3-oxoalanine Chemical compound O=CC(N)C(O)=O XMTCKNXTTXDPJX-UHFFFAOYSA-N 0.000 claims 3
- 102000005262 Sulfatase Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108060007951 sulfatase Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229920001059 synthetic polymer Polymers 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261673630P | 2012-07-19 | 2012-07-19 | |
| US61/673,630 | 2012-07-19 | ||
| PCT/US2013/050489 WO2014014821A1 (en) | 2012-07-19 | 2013-07-15 | Antibody specific for cd22 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015105588A true RU2015105588A (ru) | 2016-09-10 |
Family
ID=49949191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015105588A RU2015105588A (ru) | 2012-07-19 | 2013-07-15 | Антитело, специфическое к cd22, и способы его применения |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9181343B2 (enExample) |
| EP (2) | EP3539563A1 (enExample) |
| JP (2) | JP6578206B2 (enExample) |
| KR (1) | KR102165464B1 (enExample) |
| CN (1) | CN104582717B (enExample) |
| AU (1) | AU2013290424B2 (enExample) |
| CA (1) | CA2878642C (enExample) |
| IN (1) | IN2015DN00552A (enExample) |
| RU (1) | RU2015105588A (enExample) |
| WO (1) | WO2014014821A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102165464B1 (ko) * | 2012-07-19 | 2020-10-14 | 레드우드 바이오사이언스 인코포레이티드 | Cd22에 대해 특이적인 항체 및 이들의 사용 방법 |
| EP3110445A4 (en) | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| MD20160130A2 (ro) * | 2014-04-27 | 2017-04-30 | Ccam Biotherapeutics Ltd. | Anticorpi umanizaţi contra CEACAM1 |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| US12102689B2 (en) | 2015-11-09 | 2024-10-01 | R.P. Scherer Technologies, Llc | Anti-CD22 antibody-maytansine conjugates and methods of use thereof |
| CA3058966A1 (en) | 2017-04-14 | 2018-10-18 | Tollnine, Inc. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
| TW201920249A (zh) * | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| EP4110398A4 (en) * | 2020-02-27 | 2024-07-10 | Phanes Therapeutics, Inc. | ANTIBODIES CONJUGATED WITH FATTY ACID MOLECULES AND THEIR USES |
| CN115427458A (zh) * | 2020-02-28 | 2022-12-02 | 塔拉克治疗公司 | 转谷氨酰胺酶介导的缀合 |
| CN115667310A (zh) * | 2020-06-01 | 2023-01-31 | 创新生物有限公司 | Cd22特异性抗体及其用途 |
| US20230372522A1 (en) * | 2020-09-29 | 2023-11-23 | Kunming Sinoway Natural Pharmaceuticals Co., Ltd. | Humanized anti-cd22 recombinant immunotoxin and application thereof |
| KR20220122844A (ko) * | 2021-02-26 | 2022-09-05 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이의 용도 |
| US20240409631A1 (en) * | 2021-10-18 | 2024-12-12 | Sinomab Bioscience Limited | Aqueous formulations of an anti-cd22 antibody and uses thereof |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| TW197439B (enExample) | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
| WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
| US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| WO1993010076A1 (en) | 1991-11-22 | 1993-05-27 | The University Of Mississippi | Synthesis and optical resolution of the taxol side chain and related compounds |
| DK0617706T3 (da) | 1991-11-25 | 2001-11-12 | Enzon Inc | Multivalente antigenbindende proteiner |
| US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| WO1993023555A1 (en) | 1992-05-21 | 1993-11-25 | The Penn State Research Foundation | Cultured taxus tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US5274137A (en) | 1992-06-23 | 1993-12-28 | Nicolaou K C | Intermediates for preparation of taxols |
| US5294637A (en) | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
| US5202448A (en) | 1992-08-14 | 1993-04-13 | Napro Biotherapeutics, Inc. | Processes of converting taxanes into baccatin III |
| CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
| FR2696463B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| FR2696464B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III. |
| FR2696458B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
| FR2696462B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| FR2696461B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent. |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| US5279949A (en) | 1992-12-07 | 1994-01-18 | Board Of Trustees Operating Michigan State University | Process for the isolation and purification of taxol and taxanes from Taxus spp |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| ATE304604T1 (de) | 1993-06-24 | 2005-09-15 | Frank L Graham | Adenovirus vektoren für gentherapie |
| US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
| BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| EP0771208B1 (en) | 1994-08-12 | 2005-10-19 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| CN1510137A (zh) | 1994-12-09 | 2004-07-07 | �۹���ѧ�ĸ�����˾ | 基因的鉴定 |
| WO1996019487A1 (en) | 1994-12-22 | 1996-06-27 | Nissan Chemical Industries, Ltd. | Organobismuth derivatives and process for producing the same |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| KR100408909B1 (ko) | 1995-04-21 | 2004-04-29 | 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 | 신규펩티드유도체 |
| DE69629580D1 (de) | 1995-10-13 | 2003-09-25 | Us Gov Health & Human Serv | Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment |
| US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
| US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6254868B1 (en) | 1996-03-20 | 2001-07-03 | Immunomedics, Inc. | Glycosylated humanized B-cell specific antibodies |
| WO1998008833A1 (en) | 1996-08-26 | 1998-03-05 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
| JP4162267B2 (ja) | 1996-08-27 | 2008-10-08 | カイロン コーポレイション | Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法 |
| CA2264227A1 (en) | 1996-09-27 | 1998-04-02 | Raymond A. Firestone | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| WO1998022451A1 (en) | 1996-11-19 | 1998-05-28 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
| US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
| JP2002501488A (ja) | 1997-03-20 | 2002-01-15 | アメリカ合衆国 | Ｃｄ２２を保有する細胞および腫瘍へ標的化された、組換え抗体および免疫複合体 |
| US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| DE69831224T2 (de) | 1997-05-02 | 2006-03-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen |
| HUP0002521A3 (en) | 1997-06-20 | 2002-04-29 | Baker Norton Pharma | Onium salts of paclitaxel, process for producing them and medicaments comprising the same |
| GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
| JP4153660B2 (ja) | 1997-10-08 | 2008-09-24 | 株式会社横浜国際バイオ研究所 | タキソイド誘導体およびその製造方法 |
| US6046305A (en) | 1997-12-12 | 2000-04-04 | Macromed, Inc. | Heterofunctionalized star-shaped poly(ethylene gycols) for protein modification |
| US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
| AU782160B2 (en) | 1999-06-09 | 2005-07-07 | Immunomedics Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| SG138469A1 (en) | 2001-01-05 | 2008-01-28 | Pfizer | Antibodies to insulin-like growth factor i receptor |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| EP1448584B1 (en) | 2001-09-26 | 2010-05-19 | The Government of the United States of America as represented by The Secretary of Health and Human Services | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
| US20040001828A1 (en) * | 2002-02-21 | 2004-01-01 | Joseph Tuscano | Treatment methods using anti-CD22 antibodies |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| CA2487321A1 (en) * | 2002-06-17 | 2003-12-24 | The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services | Specificity grafting of a murine antibody onto a human framework |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| NZ551335A (en) | 2004-06-18 | 2010-03-26 | Ambrx Inc | Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker |
| CN104447992A (zh) | 2004-09-23 | 2015-03-25 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| US7255012B2 (en) | 2004-12-01 | 2007-08-14 | Rosemount Inc. | Process fluid flow device with variable orifice |
| DK1844074T3 (da) | 2005-02-03 | 2013-07-15 | Antitope Ltd | Humane antistoffer og proteiner |
| JP5142707B2 (ja) * | 2005-02-08 | 2013-02-13 | 一般財団法人化学及血清療法研究所 | 抗体の改良方法 |
| CA2644906C (en) | 2006-03-06 | 2016-05-10 | Medimmune, Inc. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| SG172656A1 (en) * | 2006-05-30 | 2011-07-28 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
| US7985783B2 (en) * | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| CA2671457C (en) * | 2006-12-01 | 2017-09-26 | Medarex, Inc. | Human antibodies that bind cd22 and uses thereof |
| WO2010096394A2 (en) * | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| PL2516460T3 (pl) * | 2009-12-22 | 2015-08-31 | Hoffmann La Roche | Agregacja zależna od sekwencji |
| UY33679A (es) * | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| KR102165464B1 (ko) * | 2012-07-19 | 2020-10-14 | 레드우드 바이오사이언스 인코포레이티드 | Cd22에 대해 특이적인 항체 및 이들의 사용 방법 |
-
2013
- 2013-07-15 KR KR1020157004194A patent/KR102165464B1/ko active Active
- 2013-07-15 IN IN552DEN2015 patent/IN2015DN00552A/en unknown
- 2013-07-15 CN CN201380043847.1A patent/CN104582717B/zh active Active
- 2013-07-15 JP JP2015523156A patent/JP6578206B2/ja active Active
- 2013-07-15 CA CA2878642A patent/CA2878642C/en active Active
- 2013-07-15 EP EP19154425.3A patent/EP3539563A1/en not_active Ceased
- 2013-07-15 RU RU2015105588A patent/RU2015105588A/ru not_active Application Discontinuation
- 2013-07-15 EP EP13820140.5A patent/EP2874650A4/en not_active Withdrawn
- 2013-07-15 WO PCT/US2013/050489 patent/WO2014014821A1/en not_active Ceased
- 2013-07-15 AU AU2013290424A patent/AU2013290424B2/en active Active
- 2013-07-15 US US13/942,140 patent/US9181343B2/en active Active
-
2015
- 2015-10-08 US US14/878,871 patent/US10259871B2/en active Active
-
2019
- 2019-02-28 US US16/289,177 patent/US20190352395A1/en not_active Abandoned
- 2019-05-17 JP JP2019093305A patent/JP2019150052A/ja not_active Withdrawn
-
2021
- 2021-08-20 US US17/408,113 patent/US12116409B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104582717B (zh) | 2018-03-13 |
| CN104582717A (zh) | 2015-04-29 |
| US20140161870A1 (en) | 2014-06-12 |
| EP2874650A1 (en) | 2015-05-27 |
| CA2878642A1 (en) | 2014-01-23 |
| EP2874650A4 (en) | 2016-03-23 |
| JP2019150052A (ja) | 2019-09-12 |
| CA2878642C (en) | 2020-12-22 |
| JP2015530973A (ja) | 2015-10-29 |
| JP6578206B2 (ja) | 2019-09-18 |
| US9181343B2 (en) | 2015-11-10 |
| US12116409B2 (en) | 2024-10-15 |
| US20190352395A1 (en) | 2019-11-21 |
| IN2015DN00552A (enExample) | 2015-06-26 |
| AU2013290424A1 (en) | 2015-02-05 |
| US10259871B2 (en) | 2019-04-16 |
| EP3539563A1 (en) | 2019-09-18 |
| US20160229911A1 (en) | 2016-08-11 |
| KR20150036700A (ko) | 2015-04-07 |
| WO2014014821A1 (en) | 2014-01-23 |
| AU2013290424B2 (en) | 2018-01-25 |
| KR102165464B1 (ko) | 2020-10-14 |
| US20220220198A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015105588A (ru) | Антитело, специфическое к cd22, и способы его применения | |
| JP7335290B2 (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| JP2015530973A5 (enExample) | ||
| JP2018520092A5 (enExample) | ||
| HRP20220172T1 (hr) | Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe | |
| HRP20200679T1 (hr) | Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji | |
| HRP20231118T1 (hr) | Sintetizirani polipeptidi koji vežu transferinske receptore | |
| SI2530091T1 (en) | PROTITELO ANTI-DLL3 | |
| RU2018141360A (ru) | Contorsbody - одноцепочечный связывающий мишень агент | |
| CN107750169A (zh) | 包含蒽环类衍生物的结合蛋白药物缀合物 | |
| HRP20231578T1 (hr) | Molekule protutijela na april i njihove uporabe | |
| HRP20201091T1 (hr) | Protutijela anti-axl | |
| HRP20200882T1 (hr) | Vezujuće molekule specifične za asct2 i njihova uporaba | |
| HRP20150934T1 (hr) | Djelovanje na abcb5 u terapiji raka | |
| RU2013110876A (ru) | Активируемые биспецифические антитела | |
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2010534191A5 (enExample) | ||
| HRP20150512T1 (hr) | Polipeptidi i polinukleotidi, te njihova uporaba kao ciljnih molekula za proizvodnju lijekova i bioloških sredstava | |
| Tomé-Amat et al. | Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts | |
| JP2019512207A5 (enExample) | ||
| KR20200092301A (ko) | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 | |
| HRP20161449T1 (hr) | Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena | |
| WO2014144911A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| HRP20180917T1 (hr) | Novi fragmenti protutijela, pripravci i njihova upotreba |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160718 |